Exact Sciences Corporation logo
Exact Sciences Corporation EXAS
report update icon

Annual report 2025
added 02-13-2026

Exact Sciences Corporation Balance Sheet 2025-2011 | EXAS

Brief overview of Exact Sciences Corporation's balance sheet structure

This overview follows the five latest available annual observations between 2021 and 2025.

Assets declined from $6.7 billion to $5.9 billion, or -12.3%. The contraction calls for context such as disposals, restructuring or weaker operations.

Liabilities expanded faster than the asset base, +4.9% versus -12.3%. Debt-service capacity deserves attention.

Equity represents 41% of assets versus 50.7% initially. The capital structure appears balanced.

The period ended with net cash: net debt stood at -$916 million. This supports financial flexibility.

Cash equals 16.3% of the balance sheet, compared with 4.7% five periods ago. This is the readily available cushion.

The balance sheet includes a negative accumulated result of -$4.7 billion. It should be assessed alongside historical profits and capital distributions.

Overall picture

Exact Sciences Corporation's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.

Annual Balance Sheet Exact Sciences Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-916 M -560 M -526 M -207 M -283 M -137 M 651 M 528 M -73 M -44.1 M -36.1 M 167 M 109 M 82.4 M 22.8 M

Long Term Debt

6.4 M 13.2 M 50 M 7.4 M 12.5 M 1.34 B 828 M 689 M 4.27 M 4.63 M 4.85 M 1 M 1 M 1 M 1 M

Long Term Debt Current

33.6 M 27.4 M 29.4 M 28.4 M 19.7 M 11.5 M 7.89 M 8 K 182 K - - - - - -

Total Non Current Liabilities

- - - - - - 981 M 706 M 10 M 11.1 M 10.7 M 5.12 M 3.56 M 2.07 M 5.48 M

Total Current Liabilities

641 M 732 M 515 M 413 M 517 M 576 M 236 M 137 M 68.1 M 30.7 M 26.7 M 17.5 M 7.75 M 11.5 M 7.98 M

Total Liabilities

3.46 B 3.53 B 3.33 B 3.18 B 3.3 B 2.1 B 1.22 B 843 M 78.1 M 41.7 M 37.4 M 22.6 M 11.3 M 13.5 M 13.5 M

Deferred Revenue

- - - - - - - - - - - - - - 4.14 M

Retained Earnings

-4.71 B -4.5 B -3.47 B -3.27 B -2.64 B -1.97 B -1.12 B -1.04 B -861 M -746 M -579 M -421 M -321 M -274 M -222 M

Total Assets

5.86 B 5.93 B 6.47 B 6.23 B 6.68 B 4.93 B 3.51 B 1.52 B 599 M 377 M 364 M 312 M 147 M 112 M 97 M

Cash and Cash Equivalents

956 M 601 M 605 M 242 M 315 M 1.49 B 177 M 160 M 77.5 M 48.9 M 41.1 M 58.1 M 12.9 M 13.3 M 35.8 M

Book Value

2.4 B 2.4 B 3.15 B 3.04 B 3.39 B 2.82 B 2.29 B 681 M 520 M 335 M 327 M 289 M 135 M 98.6 M 83.5 M

Total Shareholders Equity

2.4 B 2.4 B 3.15 B 3.04 B 3.39 B 2.24 B 2.29 B 681 M 520 M 335 M 327 M 289 M 135 M 98.6 M 83.5 M

All numbers in USD currency

Quarterly Balance Sheet Exact Sciences Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

7.8 M 9.3 M 11 M 13.2 M 14.8 M 15 M 13.1 M 7.5 M 8.4 M 7.7 M 6.8 M 7.4 M 8 M - 11.6 M 12.5 M 13.2 M 13.1 M 13.2 M 23.8 M 14 M 14 M 14 M 24 M 200 K 804 M 24.8 M 24.5 M 17.1 M 878 K 24.5 M 4.27 M 4.27 M 4.27 M 4.27 M 4.63 M 4.63 M 4.63 M 4.63 M 4.79 M 4.79 M 4.79 M 4.79 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M 1 M

Total Liabilities

3.4 B 3.33 B 3.31 B 3.53 B 3.54 B 3.48 B 3.24 B 3.33 B 3.3 B 3.3 B 3.25 B 3.18 B 3.2 B - 3.23 B 3.3 B 3.2 B 3.17 B 3.09 B 2.69 B 2.69 B 2.69 B 2.69 B 1.22 B 1.22 B 1.22 B 1.22 B 843 M 843 M 843 M 843 M 78.1 M 78.1 M 78.1 M 78.1 M 41.7 M 41.7 M 41.7 M 41.7 M 37.2 M 37.2 M 37.2 M 37.2 M 23.8 M 23.8 M 23.8 M 23.8 M 11.3 M - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - 2.3 M - 1.3 M 1 M 18.7 M 28.7 M 39.8 M 25 M 25 M 25 M 25 M 600 K 600 K 600 K 400 K 500 K 500 K 500 K 500 K 200 K 200 K 200 K 200 K - - - - - - - - - - - - 294 K 294 K 294 K 294 K 4.14 M 4.14 M 4.14 M 4.14 M 4.14 M 4.14 M 4.14 M 4.14 M

Retained Earnings

-4.62 B -4.6 B -4.6 B -4.5 B -3.63 B -3.6 B -3.58 B -3.47 B -3.42 B -3.42 B -3.34 B -3.27 B -3.14 B - -2.82 B -2.64 B -2.42 B -2.25 B -2.08 B -2.05 B -2.05 B -2.05 B -2.05 B -1.12 B -1.12 B -1.12 B -1.12 B -1.04 B -1.04 B -1.04 B -1.04 B -861 M -861 M -861 M -861 M -746 M -746 M -746 M -746 M -579 M -579 M -579 M -579 M -421 M -421 M -421 M -421 M -321 M -321 M -321 M -321 M -274 M -274 M -274 M -274 M -222 M -222 M -222 M -222 M

Total Assets

5.9 B 5.8 B 5.71 B 5.93 B 6.75 B 6.67 B 6.38 B 6.47 B 6.42 B 6.36 B 6.3 B 6.23 B 6.31 B - 6.49 B 6.68 B 6.65 B 6.72 B 6.73 B 4.93 B 4.93 B 4.93 B 4.93 B 3.51 B 3.51 B 3.51 B 3.51 B 1.52 B 1.52 B 1.52 B 1.52 B 599 M 599 M 599 M 599 M 377 M 377 M 377 M 377 M 364 M 364 M 364 M 364 M 313 M 313 M 313 M 313 M 147 M 147 M 147 M 147 M 112 M 112 M 112 M 112 M 97 M 97 M 97 M 97 M

Cash and Cash Equivalents

789 M 657 M 347 M 601 M 589 M 530 M 347 M 605 M 595 M 604 M 421 M 242 M 235 M 213 M 190 M 315 M 274 M 364 M 1.1 B 1.49 B 1.49 B 1.49 B 1.49 B 177 M 177 M 177 M 177 M 160 M 160 M 160 M 160 M 77.5 M 77.5 M 77.5 M 77.5 M 48.9 M 48.9 M 48.9 M 48.9 M 41.1 M 41.1 M 41.1 M 41.1 M 58.1 M 58.1 M 58.1 M 58.1 M 12.9 M 12.9 M 12.9 M 12.9 M 12.9 M 13.3 M 13.3 M 13.3 M 35.8 M 35.8 M 35.8 M 35.8 M

Book Value

2.5 B 2.47 B 2.4 B 2.4 B 3.21 B 3.19 B 3.13 B 3.15 B 3.12 B 3.06 B 3.06 B 3.04 B 3.11 B - 3.26 B 3.39 B 3.46 B 3.56 B 3.65 B 2.24 B 2.24 B 2.24 B 2.24 B 2.29 B 2.29 B 2.29 B 2.29 B 681 M 681 M 681 M 681 M 520 M 520 M 520 M 520 M 335 M 335 M 335 M 335 M 327 M 327 M 327 M 327 M 289 M 289 M 289 M 289 M 135 M 147 M 147 M 147 M 112 M 112 M 112 M 112 M 97 M 97 M 97 M 97 M

Total Shareholders Equity

2.5 B 2.47 B 2.4 B 2.4 B 3.21 B 3.19 B 3.13 B 3.15 B 3.12 B 3.06 B 3.06 B 3.04 B 3.11 B 3.21 B 3.26 B 3.39 B 3.46 B 3.56 B 3.65 B 2.24 B 2.24 B 2.24 B 2.24 B 1.96 B 2.29 B 2.29 B 2.29 B 447 M 681 M 681 M 681 M 520 M 520 M 520 M 520 M 335 M 335 M 335 M 335 M 327 M 327 M 327 M 327 M 289 M 289 M 289 M 289 M 135 M 135 M 135 M 135 M 98.6 M 98.6 M 98.6 M 98.6 M 83.5 M 83.5 M 83.5 M 83.5 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Exact Sciences Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 88.34 -2.0 % $ 4.13 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 5.7 0.71 % $ 528 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 14.24 1.64 % $ 1.82 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 9.61 -2.24 % $ 2.08 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Natera Natera
NTRA
$ 264.69 0.18 % $ 36.2 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.17 -0.85 % $ 812 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.4 1.45 % $ 420 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
$ 2.21 -3.07 % $ 2.94 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Neuronetics Neuronetics
STIM
$ 1.88 -2.59 % $ 124 M usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 92.44 -1.88 % $ 5.53 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 37.61 -0.45 % $ 2 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.47 -5.44 % $ 29.8 M israelIsrael
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 227.9 8.61 % $ 25.3 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Biomerica Biomerica
BMRA
$ 1.6 0.34 % $ 3.68 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.75 6.53 % $ 122 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 331.87 3.57 % $ 27.5 B schweizSchweiz
DexCom DexCom
DXCM
$ 70.48 -1.33 % $ 27.5 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.32 1.82 % $ 13.4 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA